Crohn’s disease
-
AbbVie’s Rinvoq Lands FDA Approval as First Oral Drug for Crohn’s Disease
FDA approval of blockbuster AbbVie drug Rinvoq makes it the first oral therapy for moderately to severely active Crohn’s disease. The regulatory nod is the seventh for the drug, which belongs to a class of therapies called JAK inhibitors.
-
AbbVie’s blockbuster drug Skyrizi gets FDA nod for treating Crohn’s disease
AbbVie drug Skyrizi is now approved for Crohn’s disease, making it the first treatment for the disorder that addresses a particular protein associated with inflammation. In other drug decision news, the Rhythm Pharmaceuticals product Imcivree added the rare disease Bardet-Beidl syndrome as a new approved indication.
-
Jorie Healthcare CEO Shares Why Automation is Critical to Revenue Cycle Management
The revenue cycle management business is using AI tools to automate cumbersome tasks to help hospitals operate more efficiently. It’s beginning to attract the attention of major healthcare organizations.
-
Pfizer: $6.7B Arena buyout complements rather than replaces JAK drugs
Sales of blockbuster Pfizer drug Xeljanz are under pressure from a stronger safety warning placed across that drug’s entire class. In acquiring Arena Pharmaceuticals for $6.7 billion, Pfizer gets a lead compound with a different and potentially safer approach to treating inflammatory conditions.
-
Gilead to seek FDA approval for rheumatoid arthritis drug this year
The timing of the filing appears to allay concerns that the FDA would require completion of a study evaluating the testicular safety of the drug, filgotinib, and thus push its launch date from 2020 to 2021-22, an analyst wrote.
-
Chan Zuckerberg Initiative and Helmsley Charitable Trust team up on Human Cell Atlas
The Human Cell Atlas is a global scientist-led research collaboration is attempting to create a definitive reference guide of cell types, numbers, locations, relationships and molecular components.
-
Sangamo buys stake in French firm developing cell therapies for autoimmune disease
Sangamo purchases 53 percent of France-based TxCell, will use zinc finger nuclease technology to develop CAR-Treg cells.
-
Devices & Diagnostics, Hospitals
GI gets FDA nod for PillCam SB, plans for big Q4
The third generation of Given Imaging‘s PillCam SB got FDA approval today, and President and […]